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IgMAnti-ganglioside complexes (GSCs) IgG antibodies have been reported in patients with Guillain–Barré (GBS)
or Fisher syndrome but little is known on their presence in multifocal motor neuropathy (MMN) or other
chronic immune-mediated neuropathies. We examined 24 patients with MMN, 34 with chronic
inﬂammatory demyelinating polyradiculoneuropathy (CIDP), 23 with neuropathy associated with IgM
monoclonal gammopathy (PN+IgM), 13 with GBS, 34 with motor neuron disease (MND), 24 with other
neuropathies and 20 normal subjects. Patients' sera were tested by ELISA for IgM reactivity to GM1, GM2,
GD1a, GD1b and GT1b and with GSCs made by any combination of two of these gangliosides. In all GM1
positive patients with MMN (11), PN+IgM (1), CIDP (1) and POEMS (1), binding to GM1 was abolished or
consistently reduced when tested in GSCs also containing GD1a or other gangliosides. This only occurred in
one of the three GM1 positive MND patients. In a patient with PN-IgM and anti-GM2 and GD1a IgM, both
reactivities were reduced when tested in GSCs also containing GM1. New reactivities were found in a patient
with CIDP and anti-GD1b IgM who presented an additional reactivity to GT1b/GM1 and GT1b/GM2 GSCs, and
in one with PN-IgM who had reactivity to GM2/GD1b but not to individual gangliosides. Testing for IgM
antibodies to GSCs rarely permitted to identify new reactivities in chronic immune neuropathies. IgM
binding to gangliosides was however often modiﬁed in GSCs suggesting that these reactivities may be
affected by contiguous gangliosides possibly inﬂuencing their pathogenicity.University, IRCCS Humanitas
, Italy. Tel.: +39 0282242209;
Orazio).
l rights reserved.© 2009 Elsevier B.V. All rights reserved.1. Introduction
Anti-ganglioside GM1 IgM antibodies have been reported in 30–50%
of patients with multifocal motor neuropathy (MMN) and, less
frequently, with other immune neuropathies or motor neuron disease
(MND) (van Schaik et al., 1995). The pathogenic role of these antibodies
in MMN is still unclear as well as what causes the disease in MMNGM1
negative patients. It is also unclear how similar antibodies may be
associated with and potentially responsible for different diseases
(Nobile-Orazio, 2001).
Recently, several reports described the presence of IgG antibodies
against complexes of different gangliosides, called anti-ganglioside
complexes (GSCs) antibodies, in patients with Guillain–Barré or
Fisher syndrome (Kaida et al., 2004, 2006). In these patients
antibodies to GSCs have been detected in approximately 5% of
patients not bearing antibodies to the individual gangliosides forming
the complexes (positive interaction). At the same time in somepatients themixture of some gangliosides blocked the reactivity to the
individual ganglioside forming the GSCs (negative interaction). In
these patients reactivity to GSCs was variably related to some clinical
features (Kaida et al., 2007, 2008a,b). Little is known on the presence
of anti-GSCs IgM antibodies in MMN or other chronic immune-
mediated neuropathies.
2. Material and methods
2.1. Patients
We examined 172 patients with MMN or other immune or non-
immune neuropathies and related diseases recruited and tested for
anti-nerve antibodies at our Neuropathy Clinics since 2004. All patients
had serum collected at the time of other blood tests and they all
consented to its use for research. The Internal Review Board of our
Institutions approved the study. Twenty four consecutive patients had
MMNdiagnosed according to the criteria of the European Federation of
Neurological Societies and the Peripheral Nerve Society (EFNS/PNS)
(Joint Task Force of the EFNS and the PNS, 2006) and 34 had chronic
inﬂammatory demyelinating polyradiculoneuropathy (CIDP) (Joint
Task Force of the EFNS and the PNS, 2005). We also tested 23 patients
Fig. 1. Scheme used to test for anti-ganglioside complex (GSCs) IgM antibodies by
ELISA. Patients' sera were tested with individual gangliosides (0.5 μg) and with the
combination of two gangliosides (0.5 μg each). All the wells in the ﬁrst line and column
were coated with GM1, those in the second line and column with GM2, the third line
and column with GD1a, the fourth line and column with GD1b and the ﬁfth line and
column with GT1b. Wells in the last line and column were only coated with bovine
serum albumin. The wells under the diagonal line only contained the single ganglioside
GM1, GM2, GD1a, GD1b or GT1b.
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antibodies to the myelin-associated glycoprotein (MAG) (N1/3200 by
immunoblot) (19 patients), to sulfatide (N1/16,000 by ELISA) (two
patients) or to sulfatide, GM2 and GD1a (N1/1280 by ELISA) (one
patient), 13 with GBS, 34 with motor neuron disease (MND), 24 with
neuropathy of other or undetermined causes including one with
POEMS and anti-GM1 IgM, and 20 normal subjects (NS).
2.2. Methods
Patients' sera were tested by Enzyme Linked Immunosorbent
Assay (ELISA) for IgM reactivity to the individual gangliosides GM1,
GM2, GD1a, GD1b and GT1b (0.5 μg/well for of each ganglioside) as
previously reported (Nobile-Orazio et al., 2008). To better correlate
the results obtained with ganglioside complexes, we slightly modiﬁed
the procedure by testing patients' sera at the dilution of 1:200 and by
considering positive the sera when the difference in the absorbance
betweenwells coated with the ganglioside and bovine serum albumin
(BSA) exceed 0.100. All sera were also tested for IgM reactivity to GSCs
by coating individual wells with combinations of two gangliosides at
the concentration of 0.5 μg of ganglioside per well. The scheme of the
ELISA plate used to test for anti-GSCs antibodies is illustrated in Fig. 1.
We arbitrarily considered that IgM reactivity to gangliosides was
positively affected by GSCs if the absorbance in GSCs coated wells
exceeded by at least 100% with a minimum absorbance of 0.200, the
sum of the absorbance of wells coated with the individual ganglioside
forming GSCs (positive interaction), and that it was negativelyFig. 2. Serum IgM binding by ELISA to GM1 and to GSCs containing GM1 in patient
polyradiculoneuropathy (CIDP), neuropathy associated with IgM monoclonal gammopathy
MMN, CIDP, PN-IgM and POEMS and in a patient withMND, IgM binding to GM1was consiste
and GM2. IgM binding to GM1 was not reduced in a patient with MND and was partially reaffected if the absorbance from GSCs coated wells was reduced by at
least 50% compared to the absorbance of wells coated with the
ganglioside forming the GSCs (negative interaction). All sera were
tested in duplicate and the results were always conﬁrmed in a second
separate experiment.
To determine whether the reduced IgM binding to GM1 in GSCs
containing GM1 could be caused by a reduced binding of GM1 to ELISA
wells determined by the other gangliosides forming the GSCs, we
tested IgM binding to GSCs prepared by adding to GM1 increasing
amount of GD1a (from 0.25 to 1 μg per well).3. Results
Eleven patients withMMN (46%) had serum IgM reactivity to GM1
(8) or to GM1 and GM2 (3). IgM reactivity to GM1 was also found in
one patient with CIDP (3%), one with PN-IgM and anti-MAG reactivity
(5%) and three with MND (9%). One patient with CIDP had a selective
IgM reactivity to GD1b, and one with PN-IgM to GM2 and GD1a.
In all eleven positive patients with MMN, IgM reactivity to GM1
was removed or substantially reduced (negatively affected) when
tested in the GSC GM1–GD1a (Fig. 2): in nine of them this reduction
exceed 80% and in two 50%. In ten of them reactivity was also
reduced in GM1–GD1b or GM1–GT1b or both and in four also in
GM1–GM2. A similar negative effect was observed in the GM1
positive patients with PN+IgM, CIDP and POEMS, with anti-GM1
reactivity reduced in GM1–GD1a, GM1–GD1b and in the ﬁrst two
patients also in GM1–GM2 and GM1–GT1b GSCs. This effect was
most evident in patients with high anti-GM1 reactivity, but was also
observed and reproducible in patients with low (b0.200) anti-GM1
reactivity (Fig. 2). In one of the three GM1 positive patients with
MND, IgM reactivity to GM1 was not affected when tested in any of
the GSCs containing GM1 (no interaction) (Fig. 2, MND1), while it
was almost abolished in one (MND2), and reduced by almost 50% in
another (MND3). In the patient with PN-IgM and anti-GM2 and
-GD1a IgM (and GT1b), both reactivities were markedly reduced
when GM2 was complexed with GM1, and GD1a with GM1 or GD1b
(Fig. 3a). A clearly positive interaction determined by GSCs was only
observed in two patients. One was a 67-year-old man with a 9-year
history of demyelinating sensory neuropathy with a few super-
imposed post-infective severe motor relapses that always improved
after high-dove intravenous immunoglobulin therapy. This patient
had a selective IgM reactivity to GD1b that was not affected by other
gangliosides, while IgM reactivity to GM1 and GM2 only appeared in
GSCs also containing GT1b (positive interaction) (Fig. 3b). The other
patient was a 65-year-old man with 23-year history of predomi-
nantly motor neuropathy, IgM kappa biclonal gammopathy and
marginally increased anti-MAG IgM antibodies. This patient had as with multifocal motor neuropathy (MMN), chronic inﬂammatory demyelinating
(PN-IgM), POEMS and motor neuron disease (MND). In all GM1 positive patients with
ntly reduced or abolished in GSCs also containing GD1a and, less frequently, GD1b, GT1b
duced in another one.
Fig. 3. Serum IgM binding by ELISA to gangliosides and to GSCs in one patient with
PN-IgM (a) and one with chronic inﬂammatory demyelinating polyradiculoneuro-
pathy (CIDP) (b). In PN-IgM, anti-GM2 and -GD1a IgM reactivities were markedly
reduced when GM2 was complexed with GM1, and GD1a with GM1 or GD1b. In CIDP,
IgM intensely react with GD1b and this reactivity was not or was only marginally
affected in any GSCs containing GD1b; an intense IgM reactivity also appeared with
the GSCs GM1/GT1b and GM2/GT1b in the absence of IgM reactivity to the individual
gangliosides GM1, GM2 and GT1b.
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kappa light chain, but not to the individual gangliosides.
To determine whether reduced IgM binding to GM1 could be
caused by a reduced binding of GM1 to ELISA plates caused by the
other gangliosides forming the GSCs, we tested IgM binding to GM1 in
the presence of increasing doses of GD1a (0.25 to 1 μg). In MMN and
PN-IgM patients, binding to GM1 was markedly reduced by minimal
amount of GD1a while the same amount of GD1a only marginally
affected GM1 binding in the two MND patients tested (Fig. 4).
4. Discussion
We examined patients with MMN and other chronic immune-
mediated neuropathies to determinewhether testing for antibodies to
GSCs may reveal the presence of new antibody reactivities undetect-Fig. 4. Effect on IgM reactivity toGM1of increasing amount ofGD1a in theGSCGM1/GD1a.
In patientswithMMNandPN-IgM IgMreactivity toGM1was reduced by small amounts of
GD1a, while a partial reduction of reactivity only appeared with much higher
concentration of GD1a in patients with MND (γ=μg).able with the current ELISA procedure for antibodies to individual
gangliosides. In only one patient with CIDP and high titers of
antibodies to GD1b and one with PN-IgM we found that testing for
IgM antibodies to GSCs allowed to detect an additional intense IgM
reactivity to the complexes formed by GM1 or GM2 with GT1b, as
previously reported in a few patients with GBS and high anti-GD1b
IgG (Kaida et al., 2008a), or by GM2 and GD1b, respectively, in the
absence of reactivity to the individual gangliosides. No other patient
showed new reactivities by this procedure indicating that, at odds
with GBS and FS where approximately 5–10% of the patients were
found to have antibody to GSCs in the absence of antibodies to
individual gangliosides (Kaida et al., 2006, 2007, 2008b), this seldom
occurred for IgM antibodies in patients with MMN or other chronic
immune neuropathies.
Testing for anti-GSCs IgM antibodies in our patients with increased
anti-GM1 antibodies let us identify different patterns of reactivities. In
all 11 GM1 positive patients with MMN, and in those with PN-MAG,
CIDP and POEMS, IgM reactivity to GM1 was consistently reduced
when tested in GSCs also containing GD1a and, less frequently or less
intensely, GD1b, GM2 and GT1b. This only occurred in one of the three
GM1 positive patients withMNDwhile in the other two patients, anti-
GM1 IgM reactivity was moderately or not affected. This “negative”
effect on IgM binding to GM1 in MMN was not dependent on the
blocking of GM1 binding to the ELISA wells determined by the other
gangliosides in GSCs as this only occurred inMMN, but not in all MND,
with minimal amount of GD1a. A similarly “negative” effect on IgM
binding to GM2 and GD1b in GSCs also containing GM1 was observed
in a patient with PN-IgM. These “negative” effects on antibody binding
to gangliosides have been previously reported in GBS (Kaida et al.,
2008a), suggesting that the interaction of different gangliosides may
lead not only to the formation of new antigens but also to the hiding of
reactive antigens (Willison, 2005). If we suppose indeed that variable
proportions and contiguities of individual gangliosides may be
expressed in different neural membrane, it is tempting to speculate
that this may lead to the formation of new antigens but also to the
different expressions or hiding of reactive epitopes in different neural
membranes. A brilliant support to this hypothesis was recently given
by Greeshields et al. (2009) who showed that the GM1 binding
epitope may be often hidden in mice membranes by contiguous
gangliosides and particularly by GD1a, so that the pathogenic effect of
anti-GM1 antibodies may vary depending on recognition of exposed
or cryptic antigens. This may theoretically help in explaining the
different pathogenic effects of apparently similarly reacting anti-
ganglioside antibodies. In this study we found indeed a different
pattern of reactivity between GM1 positive sera fromMMN and some
MND patients. Whether, however, these antigenic modiﬁcations also
occur on human neural membranes is not known but, if this was the
case, it would offer a clue to explain the different pathogenic effect in
vivo of similarly in vitro reacting IgM antibodies.References
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